Lupus myocarditis: marked improvement in cardiac function after intravenous immunoglobulin therapy.
Intravenous immunoglobulin (IVIg) is emerging as the mainstay in the treatment of many autoimmune diseases, including systemic lupus erythematosus. IVIg has been found to be beneficial in myocarditis due to dermatomyositis/polymyositis, Kawasaki disease, and viral myocarditis in children. We report an 18-year-old man of active lupus with worsening cardiac systolic function who did not respond to pulse methylprednisolone and cyclophosphamide, but subsequently showed an improvement in his cardiac function after IVIg administration.
Suri
Vikas
V
Post Graduate Institute of Medical Eduction and Research, Chandigarh, India.
Varma
Subhash
S
Joshi
Kiran
K
Malhotra
Pankaj
P
Kumari
Savita
S
Jain
Sanjay
S
D000293:Adolescent; D006334:Heart Function Tests; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D009205:Myocarditis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology*
D016756:Immunoglobulins, Intravenous
J Assoc Physicians India. 2004 Aug;52:673-4
15847368
Ann Intern Med. 1978 Nov;89(5 Pt 1):619-24
717930
Clin Rheumatol. 1999;18(3):238-40
11206350
Drugs Today (Barc). 1999 Jul;35(7):513-8
12973396
Mayo Clin Proc. 1999 Mar;74(3):275-84
10089998
Ann Rheum Dis. 2007 Jul;66(7):986-7
17576788
J Rheumatol. 1993 Dec;20(12):2174
8014958
Autoimmun Rev. 2008 Jun;7(6):435-9
18558358
Circ J. 2006 Feb;70(2):202-5
16434816
Arthritis Rheum. 1990 Aug;33(8):1233-9
2103727
Annu Rev Immunol. 2001;19:275-90
11244038
Circulation. 1994 Jan;89(1):252-7
8281654
Nephron. 2002 Mar;90(3):262-6
11867946